Enter the MedStartr Launchathon — Aug 1–Oct 6 in NYC
< Back to companies
McKesson

McKesson

Medicines to millions, outcomes to all

Irving, TX, US

McKesson is an American publicly traded pharmaceutical and healthcare company, the 9th largest by revenue in the United States and the largest healthcare company in the nation by delivering one-third of all pharmaceutical products used in North America.

Hero image for McKesson
Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.
Get Involved in McKesson
Claim This Profile →

How We Help

Core Technology

Pharmacy automation, data analytics, healthcare information technology services, and investments in AI and automation, including collaboration with Microsoft utilizing Azure AI for oncology documents.

Key Differentiators

Extensive logistics and distribution network (next-day delivery to 95% of customers with 99.8% order accuracy), significant market share (distributes a third of all pharmaceutical products in North America), technological innovation, strategic focus on high-growth segments (oncology and biopharma services), and commitment to health equity by improving access to medications and healthcare services for underserved populations.

Clinical Focus

Specialty care, particularly oncology and biopharmaceutical services, including solutions for community-based oncology practices and multispecialty providers in retina and ophthalmology.

Target Customers

Retail pharmacies, hospitals, physician offices, government entities, and pharmaceutical companies.

Product Stage

Mature

Company Info

Business Model
B2B
Founded
1828
Website
www.mckesson.com

Categories

Healthcare Infrastructure

Disease Areas

Technologies

Pharmacy automationdata analyticshealthcare information technologyAIautomation

Clinical & IP

🔬

Clinical Validation

Real-world evidence from iKnowMed EHR system supported first FDA approval for metastatic Merkel Cell Carcinoma drug. Exclusive specialty pharmacy partner for SKYCLARYS (omaveloxolone), FDA-approved Feb 28, 2023 for Friedreich ataxia. 25+ years oncology/rare disease expertise.

MedStartr Index Score

?
27

What do you think of McKesson?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Get Involved in McKesson